Thus, the TGF-β signature, particularly at the late stage of LC, may be considered a predictive marker for improving LC prognosis, and TGF-β inhibition has been demonstrated to reduce tumor growth and prevent LC metastasis. This evidence concerns the gene TGFB1 and laryngotracheoesophageal cleft.